Exabis Library
Welcome to the e-CCO Library!
DOP01: Extracellular Nicotinamide Phosphoribosyltransferase (eNAMPT): possible new target and biomarker in inflammatory bowel diseases
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP01: The effect of vedolizumab on CD8 T cell repertoire homogeneity and blood-gut trafficking in patients with inflammatory bowel disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP02 The dose-dependent effect of enteral nutrition on faecal microbial metabolites of healthy volunteers
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn's disease and ulcerative colitis on maintenance therapy with vedolizumab
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP020: Prediction of clinical and endoscopic remission after autologous stem cell transplantation in treatment refractory Crohn’s disease: pooled results from the ASTIC trial
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP020: Thiopurine monotherapy still has a place in the treatment of patients with mild-to-moderate Crohn’s disease in the biological era
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP021: Immunosuppressive and anti-TNF treatment is associated with a lower risk of migration from B1-to-B3-stage in Crohn’s disease: 10-year follow-up data from the Swiss IBD cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP021: Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP021: Long-term efficacy of autologous haematopoietic stem cells transplantation for refractory Crohn’s disease: 10 years of Milan experience without CD34+ cell selection
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP022: Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: a randomised controlled trial
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP022: Targeting immune cell metabolism: LYC-30937, a novel therapeutic approach for inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP022: Vedolizumab and anti-TNFα treatment effectiveness in patients with IBD treated in Germany: a retrospective chart review
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP023: Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP023: Safety and efficacy of a novel IV targeted pegylated liposomal prednisolone product (Nanocort): results from a phase 2a study in patients with active ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP023: Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trials
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP024: Electrical vagus nerve stimulation as an innovative treatment in inflammatory bowel diseases
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP024: Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infections
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP025: Clinical response to anti-MMP9 antibody (GS-5745) is accompanied by histologic improvement in ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAID
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM